NDAORALCAPSULEPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
CELEBREX (celecoxib) by Viatris (2) is cyclooxygenase inhibitors [moa]. Approved for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and 5 more indications. First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CELEBREX (celecoxib) is an oral nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), approved in 1998 for rheumatoid arthritis and other inflammatory conditions. It reduces pain, inflammation, and joint damage through targeted COX-2 inhibition while sparing COX-1. The product represents an earlier-generation approach to RA management, now competing against biologic therapies and targeted synthetic DMARDs that have become first-line agents.
$0.0BPart D
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications (8)
Worked on CELEBREX at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.